Novocure (NASDAQ: NVCR) announced that its Phase 3 TRIDENT trial failed to meet its primary endpoint, showing no statistically significant ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE